PortViewPortView
AZNH logo

AstraZeneca PLC ADRhedged (AZNH) ETF Holdings & Analysis

ETFOther

$53.74+0.03%
1-year price historyRange $40.24 – $56.90
52-week range$53.74
$38.74$56.90

What AZNH does

Under typical circumstances, this Series primarily dedicates a minimum of 95% of its net assets to American Depositary Receipts (ADRs) that represent shares of AstraZeneca PLC. It's crucial to understand that the Series will not directly acquire stock in AstraZeneca PLC. ADRs are essentially certificates issued by an American financial institution (a bank or trust company) that confirm ownership of underlying securities from a company based outside the U.S. This fund is structured as a non-diversified investment.

Fund profile

Category
Other
AUM
$1.60M
Holdings
2
52-week high
$56.90
52-week low
$38.74

Top holdings

Top 2100%
HoldingWeight
AstraZeneca plc99.33%
Cash (US$)0.67%

Sector allocation

Cash & Others0.67%
Healthcare99.33%

Geographic allocation

United Kingdom99.33%
Other0.67%

PortView Portfolio Insights

PortView analyzes how AZNH fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze AZNH in PortView →

Related securities

Related stocks

Frequently asked questions

What does AZNH track?
AZNH is the AstraZeneca PLC ADRhedged, a Other ETF.
What is the expense ratio of AZNH?
Expense ratio data for AZNH is shown on the page when available from our data provider.
What are the largest holdings in AZNH?
Top holdings include AZN, Cash (US$).
How can PortView analyze AZNH overlap with other ETFs?
PortView computes the holdings overlap between AZNH and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.